Gain Therapeutics Announces Positive Results from the

BETHESDA, Md., April 24, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology...

Related Keywords

Australia ,Switzerland ,Swiss ,Jonas Hannestad ,Matthias Alder ,Elio Ambrosio ,Nic Johnson ,Company Annual Report On Form ,European Union Horizon ,Silverstein Foundation For Parkinson ,Nasdaq ,Exchange Commission On ,Michaelj Fox Foundation For Parkinson Research ,Swiss Innovation Agency ,Exchange Commission ,Linkedin ,Gain Therapeutics Inc ,Bellberry Human Research Ethics Committee ,Gain Chief Medical Officer Jonas ,Silverstein Foundation ,Swiss Innovation ,Gain Therapeutics ,Site Directed Enzyme Enhancement Therapy ,Private Securities Litigation Reform Act ,Annual Report ,Nasdaq Ganx ,Nc ,Spanx ,T 02287 ,Arkinson 39 Sdisease ,Ingleascendingdose ,Ultipleascendingdose ,Phase1 ,Ositiveresults ,